The identified RHOA-VAV1 signaling in AITL may also be amenable to dasatinib, a multikinase inhibitor, with a promising outcomes observed from a preliminary phase I trial in AITL (165, 166). Here, VAV1 is linked to angioimmunoblastic T-cell lymphoma.